A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Study of Crizotinib (Xalkori) for ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients Versus Placebo
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAS1429
U.S. Govt. ID: NCT02201992
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare the effects of using crizotinib (also known as Xalkori) after completion of surgery, and in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer patients versus placebo. Participants will be randomized to crizotinib or placebo. Participants will take crizotinib/placebo two times per day for up to two years.
This study is closed
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with non-small cell lung cancer? Yes No
Have you undergone complete surgical resection of your stage IB, II, or IIIA NSCLC? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator